Home>>Signaling Pathways>> Stem Cell>> GSK-3>>PF-07104091 hydrate

PF-07104091 hydrate Sale

目录号 : GC62661

PF-07104091 hydrate是一种强效且选择性的 CDK2/E1 和 GSK3β 抑制剂,其 Ki 值分别为 1.16 和 537.81 nM。PF-07104091 水合物对细胞周期蛋白 E1 扩增的癌症具有抗肿瘤活性,常用于治疗 HR+/HER2- 乳腺癌和卵巢癌。

PF-07104091 hydrate Chemical Structure

规格 价格 库存 购买数量
5 mg
¥6,750.00
现货
10 mg
¥10,710.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

OVCAR3

Preparation Method

OVCAR3 cells were treated with (37-3000) nM PF-07104091 for 24 hours.

Reaction Conditions

PF-07104091(37、111、333、1000、3000) nM;24h

Applications

PF-07104091 inhibits the expression of biomarkers t-Rb, t-NCL, pRB S8078/811, and p-NCL T84 in OVCAR3 cells.

Animal experiment [1]:

Animal models

ovarian cancer modle

Preparation Method

OVCAR3 tumors in mice treated with PF-07104091 orally (PO) twice per day (BID) for 25 day.

Dosage form

PF-07104091 (25、75、175)mpk;25 day; twice per day;PO

Applications

Tumor growth inhibition (TGI) profile of OVCAR3 tumors in mice treated with PF-07104091 orally (PO) twice per day (BID).

References:
[1]. Shen C, Zhang Q, Almaden J, et al. PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2-breast cancer and CCNE1 high ovarian cancer[J]. Cancer Research, 2024, 84(6_Supplement): 5709-5709.

产品描述

PF-07104091 hydrate is a potent and selective inhibitor of CDK2/E1 and GSK3β with Kis of 1.16 and 537.81 nM[1], respectively. PF-07104091 hydrate has antitumor activity against cyclin E1-amplified cancers and is commonly used to treat HR+/HER2- breast cancer and ovarian cancer[2].

PF-07104091 (37-3000nM, 24h) inhibits the expression of biomarkers t-Rb, t-NCL, pRB S8078/811, and p-NCL T84 in OVCAR3 cells[1].PF-07104091(0.01-10mM, 3day) inhibits the proliferation of tumor cells (TOV-21G, HCT116) [3].

PF-07104091 (25、75、175 mpk,25 day; twice per day;PO) inhibits tumor growth (TGI) of OVCAR3 tumors mice[1] .In nude mouse model of HCT116 transplanted tumor, PF-07104091(50 mg/kg, 14 day) reduced tumor volume by nearly 69.81% and tumor weight by nearly 60.16%.[3]

References:
[1].Shen C, Zhang Q, Almaden J, et al. PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2-breast cancer and CCNE1 high ovarian cancer[J]. Cancer Research, 2024, 84(6_Supplement): 5709-5709. 
[2]. Douglas Carl BEHENNA, et al. Cdk2 inhibitors. WO2020157652A2.
[3]. Liu, Z.; Yang, Y.; Sun, X.; Ma, R.; Zhang, W.; Wang, W.; Yang, G.; Wang, H.; Zhang, J.; Wang, Y.; et al. Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53. Molecules 2024, 29, 725.

PF-07104091 hydrate是一种强效且选择性的 CDK2/E1 和 GSK3β 抑制剂,其 Ki 值分别为 1.16 和 537.81 nM[1]。PF-07104091 水合物对细胞周期蛋白 E1 扩增的癌症具有抗肿瘤活性,常用于治疗 HR+/HER2- 乳腺癌和卵巢癌[2]

PF-07104091(37-3000nM,24小时)抑制OVCAR3细胞中生物标志物t-Rb,t-NCL,pRB S8078/811和p-NCL T84的表达[1]。PF-07104091(0.01-10mM,3day)抑制肿瘤细胞(TOV-21G,HCT116)的增殖[3]

PF-07104091(25、75、175 mpk,25 天;PO)抑制OVCAR3肿瘤小鼠的肿瘤生长(TGI)。在HCT116裸鼠模型中,PF-07104091(50 mg/kg,14天)使肿瘤体积减少了近69.81%,肿瘤重量减少了近60.16%[3]

Chemical Properties

Cas No. SDF
分子式 C19H30N6O5 分子量 422.48
溶解度 储存条件 4°C, away from moisture and light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.367 mL 11.8349 mL 23.6698 mL
5 mM 0.4734 mL 2.367 mL 4.734 mL
10 mM 0.2367 mL 1.1835 mL 2.367 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置